SANOFI-ADR (SNY) Stock Price & Overview
NASDAQ:SNY • US80105N1054
Current stock price
The current stock price of SNY is 43.6 USD. Today SNY is down by -0.07%. In the past month the price decreased by -7.29%. In the past year, price decreased by -24.5%.
SNY Key Statistics
- Market Cap
- 105.306B
- P/E
- 9.62
- Fwd P/E
- 8.87
- EPS (TTM)
- 4.53
- Dividend Yield
- 5.38%
SNY Stock Performance
SNY Stock Chart
SNY Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to SNY. When comparing the yearly performance of all stocks, SNY is a bad performer in the overall market: 81.53% of all stocks are doing better.
SNY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to SNY. While SNY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
SNY Earnings
On January 29, 2026 SNY reported an EPS of 0.77 and a revenue of 11.30B. The company beat EPS expectations (4.58% surprise) and missed revenue expectations (-2.08% surprise).
SNY Forecast & Estimates
30 analysts have analysed SNY and the average price target is 57.52 USD. This implies a price increase of 31.92% is expected in the next year compared to the current price of 43.6.
For the next year, analysts expect an EPS growth of 8.41% and a revenue growth 6.58% for SNY
SNY Groups
Sector & Classification
SNY Financial Highlights
Over the last trailing twelve months SNY reported a non-GAAP Earnings per Share(EPS) of 4.53. The EPS increased by 1.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.71% | ||
| ROA | 9.85% | ||
| ROE | 17.49% | ||
| Debt/Equity | 0.22 |
SNY Ownership
SNY Latest News, Press Relases and Analysis
SNY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.18 | 929.285B | ||
| JNJ | JOHNSON & JOHNSON | 20.74 | 582.039B | ||
| MRK | MERCK & CO. INC. | 22.34 | 285.833B | ||
| PFE | PFIZER INC | 8.9 | 151.141B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.33 | 120.315B | ||
| ZTS | ZOETIS INC | 16.34 | 48.807B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.83 | 26.334B | ||
| VTRS | VIATRIS INC | 5.39 | 15.555B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.81 | 11.405B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.983B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.157B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.94B | ||
| LGND | LIGAND PHARMACEUTICALS | 23.9 | 4.046B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SNY
Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Company Info
IPO: 2002-07-01
SANOFI-ADR
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE 75008 FR
CEO: Paul Hudson
Employees: 82878
Phone: 33153774000
SANOFI-ADR / SNY FAQ
What does SNY do?
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Can you provide the latest stock price for SANOFI-ADR?
The current stock price of SNY is 43.6 USD. The price decreased by -0.07% in the last trading session.
Does SANOFI-ADR pay dividends?
SANOFI-ADR (SNY) has a dividend yield of 5.38%. The yearly dividend amount is currently 2.19.
How is the ChartMill rating for SANOFI-ADR?
SNY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about SANOFI-ADR (SNY) stock?
30 analysts have analysed SNY and the average price target is 57.52 USD. This implies a price increase of 31.92% is expected in the next year compared to the current price of 43.6.
Can you provide the sector and industry classification for SANOFI-ADR?
SANOFI-ADR (SNY) operates in the Health Care sector and the Pharmaceuticals industry.
What is the market capitalization of SNY stock?
SANOFI-ADR (SNY) has a market capitalization of 105.31B USD. This makes SNY a Large Cap stock.